Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVFM NASDAQ:EVLO NASDAQ:GLMD NASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01+1.5%$0.01$0.00▼$0.02$875K-1.32191,411 shs80,507 shsEVLOEvelo Biosciences$0.00$0.00▼$0.00$2K2.032,580 shsN/AGLMDGalmed Pharmaceuticals$0.60-8.9%$0.62$0.41▼$2.34$3.29M0.62176,591 shs110,127 shsREVBRevelation Biosciences$0.98-4.9%$1.17$0.88▼$39.60$3.83M-0.1484,293 shs90,802 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences0.00%+3.08%-24.72%-22.99%-20.24%EVLOEvelo Biosciences0.00%0.00%0.00%0.00%-66.67%GLMDGalmed Pharmaceuticals0.00%-1.80%-18.81%-2.12%-54.20%REVBRevelation Biosciences0.00%+2.01%-18.39%-33.38%-97.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01+1.5%$0.01$0.00▼$0.02$875K-1.32191,411 shs80,507 shsEVLOEvelo Biosciences$0.00$0.00▼$0.00$2K2.032,580 shsN/AGLMDGalmed Pharmaceuticals$0.60-8.9%$0.62$0.41▼$2.34$3.29M0.62176,591 shs110,127 shsREVBRevelation Biosciences$0.98-4.9%$1.17$0.88▼$39.60$3.83M-0.1484,293 shs90,802 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences0.00%+3.08%-24.72%-22.99%-20.24%EVLOEvelo Biosciences0.00%0.00%0.00%0.00%-66.67%GLMDGalmed Pharmaceuticals0.00%-1.80%-18.81%-2.12%-54.20%REVBRevelation Biosciences0.00%+2.01%-18.39%-33.38%-97.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 1.00SellN/AN/AREVBRevelation Biosciences 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest REVB, GLMD, EVLO, and EVFM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/27/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/21/2026GLMDGalmed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$11.39M0.08N/AN/A($2.64) per share0.00EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$2.88 per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$3.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$0.03N/AN/AN/A-46.42%-91.97%-61.93%N/AEVLOEvelo Biosciences-$114.53M-$8.81N/AN/AN/AN/AN/AN/AN/AGLMDGalmed Pharmaceuticals-$10.31M-$1.24N/AN/AN/AN/A-29.43%-26.00%5/20/2026 (Estimated)REVBRevelation Biosciences-$8.91M-$39.48N/AN/AN/AN/A-107.65%-87.98%N/ALatest REVB, GLMD, EVLO, and EVFM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026REVBRevelation Biosciences-$1.15-$2.71-$1.56-$2.71N/AN/A2/26/2026Q4 2025REVBRevelation Biosciences-$1.41-$1.65-$0.24-$1.65N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.110.09EVLOEvelo BiosciencesN/AN/AN/AGLMDGalmed PharmaceuticalsN/A6.556.55REVBRevelation BiosciencesN/A10.025.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%EVLOEvelo Biosciences0.31%GLMDGalmed Pharmaceuticals76.14%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.01%EVLOEvelo Biosciences1.02%GLMDGalmed Pharmaceuticals19.80%REVBRevelation Biosciences8.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences120132.53 million113.12 millionNot OptionableEVLOEvelo Biosciences12018.84 million18.79 millionNo DataGLMDGalmed Pharmaceuticals205.48 million4.39 millionNot OptionableREVBRevelation Biosciences103.91 million3.59 millionNot OptionableREVB, GLMD, EVLO, and EVFM HeadlinesRecent News About These CompaniesRevelation Biosciences, Inc. Releases Corporate Update Letter to StockholdersMay 11, 2026 | accessnewswire.comAREVB Poised for Big YearMay 8, 2026 | finance.yahoo.comRevelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026May 7, 2026 | accessnewswire.comARevelation Biosciences Announces Formation of Acute Kidney Injury Advisory BoardApril 6, 2026 | accessnewswire.comARevelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical StudyMarch 30, 2026 | oklahoman.comORevelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comREMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 24, 2026 | accessnewswire.comARevelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceMarch 19, 2026 | accessnewswire.comARevelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025February 26, 2026 | accessnewswire.comARevelation Biosciences (REVB) price target increased by 300.00% to 86.70February 4, 2026 | msn.comREVB Comes to Agreement with FDAJanuary 29, 2026 | finance.yahoo.comREVB stock drops 10% after company announces third reverse split in a yearJanuary 26, 2026 | msn.comRevelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026January 26, 2026 | accessnewswire.comARevelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross ProceedsJanuary 23, 2026 | accessnewswire.comARevelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKIJanuary 21, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care NephrologyJanuary 14, 2026 | finanznachrichten.deRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)January 14, 2026 | accessnewswire.comARevelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 12, 2026 | accessnewswire.comARevelation Biosciences, Inc.: Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical DevelopmentJanuary 8, 2026 | finanznachrichten.deRevelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical DevelopmentJanuary 7, 2026 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeREVB, GLMD, EVLO, and EVFM Company DescriptionsEvofem Biosciences NASDAQ:EVFM$0.0067 +0.00 (+1.52%) As of 05/15/2026 03:45 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Evelo Biosciences NASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Galmed Pharmaceuticals NASDAQ:GLMD$0.60 -0.06 (-8.88%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$0.61 +0.01 (+1.33%) As of 05/15/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.Revelation Biosciences NASDAQ:REVB$0.98 -0.05 (-4.92%) Closing price 05/15/2026 03:59 PM EasternExtended Trading$0.98 0.00 (-0.34%) As of 05/15/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In Robinhood, SoFi, and Webull Are Telling Very Different Stories Viking Sails to All-Time Highs—Fundamentals Signal More to Come Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
